BPH GlobalASX:BP8 Days Inventory is 14.30 as of Dec. 2025, which is 66% below its 10-year median of 41.56. The stock has 6 warning signs investors should review. Among 917 Drug Manufacturers companies, BPH Global ranks better than 98.36% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). BPH Global's Average Total Inventories for the
six
months ended in Dec. 2025 was A$0.11 Mil. BPH Global's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$1.44 Mil.
Hence, BPH Global's Days Inventory for the
six
months ended in Dec. 2025 was 14.30.
The historical rank and industry rank for BPH Global's Days Inventory or its related term are showing as below:
ASX:BP8'
s Days Inventory Range Over the Past 10 Years
Min: -0.55 Med: 41.56 Max: 395.82
Current: 19.27
During the past 13 years, BPH Global's highest Days Inventory was 395.82. The lowest was -0.55. And the median was 41.56.
ASX:BP8's Days Inventory is ranked better than 98.36% of 917
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs ASX:BP8: 19.27
BPH Global's Days Inventory
declined
from Dec. 2024 (221.28) to Dec. 2025 (14.30).
Inventory Turnover measures how fast the company turns over its inventory within a year.
BPH Global's Inventory Turnover for the
six
months ended in Dec. 2025 was 12.76.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BPH Global's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.08.
BPH Global (ASX:BP8) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BPH Global's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BPH Global's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BPH Global Days Inventory Related Terms
BPH Global Days Inventory Historical Data
* Premium members only.
The historical data trend for BPH Global's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's Days Inventory distribution charts can be found below:
* The bar in red indicates where BPH Global's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPH Global (ASX:BP8) has a Days Inventory of 14.30 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BPH Global and its competitors. This is 66% below median its historical median of 41.56. According to the industry distribution chart, BPH Global ranks #15 out of 917 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is BPH Global's Days Inventory too high?
BPH Global's current Days Inventory of 14.30 is 66% below median its 10-year median of 41.56. The Drug Manufacturers industry median Days Inventory is 164.48. BPH Global's value of 14.30 is 91.3% below this industry median. Based on the distribution chart, BPH Global ranks #15 out of 917 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does BPH Global's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #15 out of 917 companies for Days Inventory. This places BPH Global in the top 2% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.48. BPH Global's value of 14.30 is 91.3% below this benchmark. While the company's 10-year median is 41.56 vs. the industry median of 164.48, BPH Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BPH Global's current Days Inventory of 14.30 is 91.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BPH Global and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BPH Global's current Days Inventory is 14.30, which is 66% below median its own 10-year median of 41.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current Days Inventory of 14.30. The current Days Inventory is 14.30, which is 66% below median its 10-year median of 41.56 and 91.3% below the Drug Manufacturers industry median of 164.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current Days Inventory is 14.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 